Google DeepMind's Drug discovery ARM, Isomorphic Lab is ready to start Human Examination the AI-designed drugs. In an interview with Fortune, Colin Murdochpresident of Isomorphic Lab Google Deepmind's chief business officer said the company is “very close” to starting human trials for these drugs. This development implies a potential step in the isomorphic lab after years of work on the design of AI-assisted drugs. Isomorphic Labs were established as another entity deepmind 2021. That foundation arises from Alphafoldthe remarkable AI system developed by DeepMind is recognized for its ability to predict protein structure fairly accurately.
What Google Deepmind executives said about starting human trials for AI-designed drugs
In an interview with Fortune in Paris, Murdoch said: “There's someone sitting in our office in King's Cross, London, and we're working with AI to design drugs for cancer.“The next big milestone is actually going out for clinical trials and starting to put these things into humans. We're very close now.” He added.Isomorphic Labs, a company that was launched from Deepmind in 2021, was born from Alphafold, an AI system known for accurately predicting protein structure. Over time, AlphaFold has evolved to model the interactions between proteins and molecules such as DNA and drugs, greatly promoting its utility in drug discovery and accelerated the development of new drugs.Speaking about Alphafold, Murdoch emphasized: “This was the inspiration for the isomorphic lab. It really shows that you can do something very basic with AI that helps you unlock drug discovery.”In 2024, the same model lab partnered Novartis and Eli Lily After releasing AlphaFold 3, by April 2025 it raised $600 million in its first external funding round led by Thrive Capital.These moves support the goal of creating a “world-class drug design engine” that combines AI and pharma expertise to develop medicines more efficiently. In addition to supporting existing drug programs, the company is developing candidates in areas such as oncology and immunology for future licensing.“We identify unmet needs and launch our own drug design program. We develop them and put them in human clinical trials… We don't have that yet, but we're making good progress.”Murdoch explained.Currently, pharmaceutical companies have invested millions in drug development, and in many cases, they have only 10% success rates in the trial. Murdoch aims to use Alphafold's technology to significantly improve these odds, ideally achieving a point where researchers can reach full confidence in the effectiveness of the drug before human testing begins.“We're trying to do all of this. We're speeding up them, reducing costs, but we're really improving the chances of success too.” I hope that one day they'll say. All of these come with these amazing AI tools. ” Murdoch continued.
